Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 5/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 7/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 3/20 | 0.32 |
| ▸ | MET | P08581 | 2/20 | 0.32 |
| ▸ | RAF1 | P04049 | 1/20 | 0.30 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938732 | 0.95 | RIPK1 (0.35) | FGFR1RIPK1MAP2K1EGFRERBB2 | |
| SCHEMBL938736 | 0.94 | RIPK1 (0.39) | FGFR1RIPK1MAP2K1EGFRERBB2 | |
| SCHEMBL939532 | 0.93 | FGFR1 (0.37) | FGFR1RIPK1MAP2K1EGFRERBB2 | |
| SCHEMBL939854 | 0.90 | FGFR1 (0.36) | FGFR1RIPK1MAP2K1EGFRERBB2 | |
| SCHEMBL940567 | 0.90 | AURKB (0.36) | FGFR1RIPK1MAP2K1EGFRERBB2 | |
| SCHEMBL940870 | 0.90 | RIPK1 (0.35) | FGFR1RIPK1MAP2K1AURKAAURKB | |
| SCHEMBL941500 | 0.86 | MAP2K1 (0.40) | FGFR1RIPK1MAP2K1EGFRERBB2 | |
| SCHEMBL940250 | 0.85 | RIPK1 (0.38) | FGFR1RIPK1MAP2K1EGFRERBB2 | |
| SCHEMBL938738 | 0.85 | MAP2K1 (0.38) | FGFR1RIPK1MAP2K1EGFRERBB2 | |
| SCHEMBL938373 | 0.85 | FGFR1 (0.37) | FGFR1RIPK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957078-B1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC (US) | 2013-08-28 | — | — | EP | claimed |
| US-8338594-B2 | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase | BAYER HEALTHCARE LLC (US) | 2012-12-25 | — | — | US | claimed |
| US-20110021518-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC. (US) | 2011-01-27 | — | — | US | claimed |
| EP-1957078-B1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC (US) | 2013-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021518-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | AURKC, AURKA, PLK1 | FGFR1 776/4885RIPK1 333/4885MAP2K1 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.